AI News Sentiment & Analysis
Aquestive Therapeutics, Inc. (AQST) — AI News Sentiment & Analysis
3 recent AI analyses of Aquestive Therapeutics, Inc. (AQST) stock news and press releases, with sentiment and confidence scoring updated continuously.
Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree
BullishCapital ActionCompletion of the $150 million debt refinancing, which provides funding and flexibility for the potential FDA approval and commercial launch of Anaphylm. (Timing: Within 12 months (dependent on FDA approval timeline for Anaphylm).)May 12, 2026Aquestive Therapeutics to Present New Clinical Data on Anaphylm™ (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual Meeting
BullishPresentation of positive new clinical data for Anaphylm™ at the 2026 AAAAI Annual Meeting, showcasing its potential as a first-in-class oral treatment for anaphylaxis. (Timing: February 27 - March 2, 2026)Feb 20, 2026Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer
BullishThe key catalyst is the successful resubmission and subsequent FDA approval of the Anaphylm New Drug Application, supported by the new Chief Medical Officer. (Timing: Approval is estimated within 6-18 months, considering the company is currently preparing the resubmission.)Feb 18, 2026
Want the full picture?
These are AI-read press-release catalysts. Sign up to see complete investment theses, valuation rationales, entry/exit strategies, and get real-time alerts.
Sign Up for FreeFrequently Asked Questions
Is Aquestive Therapeutics, Inc. (AQST) bullish or bearish right now?
AI Sentiment on AQST: 3 Bullish.
What was the latest AI analysis for Aquestive Therapeutics, Inc. (AQST)?
The latest analysis was published on 5/12/2026 with the headline: "Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree".
How does Bekodia analyze Aquestive Therapeutics, Inc. (AQST) stock?
Bekodia uses advanced AI models to process Aquestive Therapeutics, Inc. (AQST) press releases and news in real-time, extracting sentiment, confidence scores, and key investment catalysts while filtering out market noise.